Vernx Biotechnology’s branched fat patented technology platform has led to the development of three specific products with a focus on specific applications – dietary supplements, infant formula and pharmaceuticals.
The global probiotic and gut health supplement market is significant and is the fastest growing nutritional market sector. Our branched fats platform have a range of positive effects on microbiota ecology and as well as the gut epithelial cells, is a novel and unique offering to this segment. Vernx launched its first product in this market in July 2020.
Branched fats are a unique and important fatty acid found in human breast milk but not currently in infant formula. With growing interest in infant gut health, Vernx is developing the world’s first branched fat infant formula ingredient and will be available for clinical trials in Q1 2022.
Branched fats are a significant component of vernix caseosa (white waxy substance on newborn baby skin). It is now understood that vernix caseosa sloughs off into the amniotic fluid and is ingested by the developing foetus. It is important in the early microbiota seeding, gut epithelial cell development and immunity. As this occurs in the last trimester preterm premature babies do not get this essential fatty acid and also suffer a range of severe gastrointestinal diseases. We are developing a proprietary product targeting the treatment of necrotizing enterocolitis. Following on from very encouraging in-vivo studies, development and registration of a proprietary active ingredient is underway.